The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges

[1]  Deepak L. Bhatt,et al.  Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19 , 2021, JAMA network open.

[2]  R. Mehran,et al.  Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials , 2021, European heart journal. Cardiovascular pharmacotherapy.

[3]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[4]  N. Chan,et al.  Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality? , 2021, European heart journal.

[5]  Peter J. Godolphin,et al.  Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. , 2021, JAMA.

[6]  Suthan Srigunapalan,et al.  Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis , 2021, TH Open.

[7]  S. Ram,et al.  The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis , 2021, Annals of Internal Medicine.

[8]  Á. Avezum,et al.  Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[9]  A. Doroshenko.  The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions-Ending the COVID-19 Pandemic. , 2021, JAMA network open.

[10]  D. Gaudet,et al.  Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial , 2021, The Lancet Respiratory Medicine.

[11]  M. Landray,et al.  Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, The Lancet Respiratory Medicine.

[12]  A. Sette,et al.  Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection , 2021, The Journal of clinical investigation.

[13]  M. H. Bashari,et al.  The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis , 2021, Clinical Epidemiology and Global Health.

[14]  S. Middeldorp,et al.  COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year , 2021, The Lancet Haematology.

[15]  J. Ioannidis,et al.  Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently? , 2021, Canadian Journal of Cardiology.

[16]  C. Creech,et al.  SARS-CoV-2 Vaccines. , 2021, JAMA.

[17]  M. T. Medina,et al.  Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results , 2020, The New England Journal of Medicine.

[18]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19 , 2020, The New England Journal of Medicine.

[19]  E. Turillazzi,et al.  Autopsy findings in COVID-19-related deaths: a literature review , 2020, Forensic Science, Medicine and Pathology.

[20]  B. Firestein,et al.  Colchicine in COVID-19: an Old Drug, New Use , 2020, Current Pharmacology Reports.

[21]  F. Martinez,et al.  Severe Covid-19. , 2020, The New England journal of medicine.

[22]  Carlos Del Rio,et al.  Mild or Moderate Covid-19. , 2020, The New England journal of medicine.

[23]  Manesh R. Patel,et al.  Rivaroxaban in Peripheral Artery Disease after Revascularization. , 2020, The New England journal of medicine.

[24]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[25]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[26]  J. Haybittle,et al.  Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.